Journal: Genes

Article Title: Suicide-Related Single Nucleotide Polymorphisms, rs4918918 and rs10903034 : Association with Dementia in Older Adults

doi: 10.3390/genes13112174

Figure Lengend Snippet: Polymorphism descriptions.

Article Snippet: rs4918918 , T > C , SORBS1 , C_3178855_10 , CBL-associated protein that is involved in insulin signaling , Suicide attempts in affective disorders , [ ] .

Techniques: Gene Assay, Binding Assay

Journal: Genes

Article Title: Suicide-Related Single Nucleotide Polymorphisms, rs4918918 and rs10903034 : Association with Dementia in Older Adults

doi: 10.3390/genes13112174

Figure Lengend Snippet: Distribution of alleles and test for Hardy–Weinberg equilibrium.

Article Snippet: rs4918918 , T > C , SORBS1 , C_3178855_10 , CBL-associated protein that is involved in insulin signaling , Suicide attempts in affective disorders , [ ] .

Techniques: Control

Journal: Genes

Article Title: Suicide-Related Single Nucleotide Polymorphisms, rs4918918 and rs10903034 : Association with Dementia in Older Adults

doi: 10.3390/genes13112174

Figure Lengend Snippet: Analysis of allele frequency association with study groups and association between genotypes and the MMSE score. Age was used as a covariate.

Article Snippet: rs4918918 , T > C , SORBS1 , C_3178855_10 , CBL-associated protein that is involved in insulin signaling , Suicide attempts in affective disorders , [ ] .

Techniques:

Journal: PLoS ONE

Article Title: Characterization of single cell derived cultures of periosteal progenitor cells to ensure the cell quality for clinical application

doi: 10.1371/journal.pone.0178560

Figure Lengend Snippet: Mean values of 3 clonal cultures with osteo-chondrogenic and 3 multipotent osteo-, chondro- and adipogenic differentiation potential were given. Absence of hematopoietic cell surface marker CD14, CD34, and CD45 and nearly 100% marker presentation of CD44, CD73, CD90, CD105, and CD166 in clonal cultures with a multipotent and with an osteo-/chondrogenic differentiation capacity were presented.

Article Snippet: Fluorescein isothiocyanate (FITC) labelled mouse anti-human CD105 (endoglin; SH-2) was purchased by Acris Antibodies (Acris Antibodies, Hiddenhausen, Germany).

Techniques: Marker

Journal: Translational Oncology

Article Title: ZNF37A downregulation promotes TNFRSF6B expression and leads to therapeutic resistance to concurrent chemoradiotherapy in rectal cancer patients

doi: 10.1016/j.tranon.2024.102203

Figure Lengend Snippet: ZNF37A increases the sensitivity of colorectal cancer cells to chemoradiotherapy. A. Expression level of ZNF37A between responders and non-responders in 44 training sample set and 81 all sample set. Data were mean±SEM. B. Kaplan-Meier curves of disease-free survival according to ZNF37A expression in 44 training sample set and 81 all sample set. Low and high ZNF37A groups were separated according to the median of the chip detection values. C. Colony formation assays of HCT8-Vector, HCT8-ZNF37A, LoVo-Vector and LoVo-ZNF37A cells. DMSO, control group treated with Dimethyl sulfoxide. CT/RT, the treatment group treated with radiotherapy (2 Gy) and chemotherapy (5 μg/ml 5-Fu and 1 μg/ml Oxaliplatin). D. Colony formation assays of HCT116-shCtrl, HCT116-ZNF37A sh1, HCT116-ZNF37A sh2, LoVo-shCtrl, LoVo-ZNF37A sh1 and LoVo-ZNF37A sh2 cells. Right panels represented data (mean±SEM) from three independent experiments. E. Images of subcutaneous tumors at the end of the treatment period, proliferation curves, and tumor weights for HCT8-Vector and HCT8-ZNF37A tumors transplanted in nude mice with or without chemoradiotherapy treatment. Data were presented as mean±SEM of tumor volumes from five mice at each time point. F. Images of subcutaneous tumors at the end of the treatment period, proliferation curves, and tumor weights for HCT116-shCtrl, HCT116-ZNF37A sh1, and HCT116-ZNF37A sh2 tumors transplanted in nude mice with or without chemoradiotherapy treatment. Data were presented as mean±SEM of tumor volumes from five mice at each time point. *, P < 0.05; **, P < 0.01; ***, P < 0.001 and ns, not significant of Student's t -test (C-E). *, P < 0.05; **, P < 0.01 and ns, not significant of one-way ANOVA (F).

Article Snippet: Male BALB/c mice aged 4–6 weeks (Beijing IDMO Co.) were injected subcutaneously with HCT8−Vector, HCT8−ZNF37A, HCT116−shCtrl, HCT116−sh1, and HCT116−sh2 CRC cells (2 × 10 6 ) and housed for 30 days.

Techniques: Expressing, Plasmid Preparation, Control

Journal: Translational Oncology

Article Title: ZNF37A downregulation promotes TNFRSF6B expression and leads to therapeutic resistance to concurrent chemoradiotherapy in rectal cancer patients

doi: 10.1016/j.tranon.2024.102203

Figure Lengend Snippet: ZNF37A enhances sensitivity to chemoradiotherapy by promoting apoptosis in CRC cells. A. Analysis of the expression profiling data revealed that there were 372 genes significantly negatively correlated with ZNF37A. KEGG pathway enrichment result of 372 genes negatively related to the expression of ZNF37A and 8 candidate apoptosis-related genes were selected from the 372 genes. B. The mRNA expression levels of ZNF37A and eight apoptosis related genes were detected by real-time quantitative PCR in LoVo-Vector and LoVo-ZNF37A cells. C. The mRNA expression levels of ZNF37A and eight apoptosis related genes were detected by real-time quantitative PCR in LoVo-shCtrl, LoVo-ZNF37A sh1 and LoVo-ZNF37A sh2cells. D-E. Western blot analysis of ZNF37A, TNFRSF6B and several apoptosis-related protein levels in chemoradiotherapy-treated and untreated groups of ZNF37A-OE HCT8 and LoVo cells (D), ZNF37A-KD HCT116 and LoVo cells (E). F-G. Proportion of apoptotic cells in the chemoradiotherapy-treated and untreated groups of ZNF37A-OE HCT8 and LoVo cells (F), ZNF37A-KD HCT116 and LoVo cells (G). Data were shown as mean±SEM from three independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001 and ns, not significant of Student's t -test (B, F). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001 and ns, not significant of one-way ANOVA (C, G).

Article Snippet: Male BALB/c mice aged 4–6 weeks (Beijing IDMO Co.) were injected subcutaneously with HCT8−Vector, HCT8−ZNF37A, HCT116−shCtrl, HCT116−sh1, and HCT116−sh2 CRC cells (2 × 10 6 ) and housed for 30 days.

Techniques: Expressing, Real-time Polymerase Chain Reaction, Plasmid Preparation, Western Blot

Journal: Translational Oncology

Article Title: ZNF37A downregulation promotes TNFRSF6B expression and leads to therapeutic resistance to concurrent chemoradiotherapy in rectal cancer patients

doi: 10.1016/j.tranon.2024.102203

Figure Lengend Snippet: ZNF37A binds to the TNFRSF6B promoter region and represses its transcriptional activity. A. Differences of TNFRSF6B Expression between responders and non-responders in the 44 training sample set. The values of different groups were the median and extreme values of chip detection values. B-C. Negative correlation between ZNF37A and TNFRSF6B expression in the 44 training sample set and 81 all sample set. D. Eleven pairs of primers designed for continuous segments covering 3000 bp upstream and 1000 bp downstream of the transcription start site (TSS) of TNFRSF6B and the ChIP-qPCR results showed significant enrichment of ZNF37A in the fourth and tenth primer regions. E. ChIP-qPCR results and gel diagram of ChIP-qPCR products for the fourth and tenth primer regions mentioned above in the LoVo-shCtrl, LoVo-sh1 and LoVo-sh2 cell lines. F. Luciferase activity of transfection of full-length and different truncated recombinant plasmid of the TNFRSF6B promoter region in HCT8-Vector, HCT8-ZNF37A, LoVo-Vector and LoVo-ZNF37A cells. G. Luciferase activity of transfection of full-length and different truncated recombinant plasmid of the TNFRSF6B promoter region in HCT116-shCtrl, HCT116-ZNF37A sh1, HCT116-ZNF37A sh2, LoVo-shCtrl, LoVo-ZNF37A sh1 and LoVo-ZNF37A sh2 cells. Data were shown as mean±SEM from three independent experiments. *, P < 0.05; **, P < 0.01 of Student's t -test (D, F). *, P < 0.05; **, P < 0.01; ***, P < 0.001 and ****, P < 0.0001 of one-way ANOVA (E, G).

Article Snippet: Male BALB/c mice aged 4–6 weeks (Beijing IDMO Co.) were injected subcutaneously with HCT8−Vector, HCT8−ZNF37A, HCT116−shCtrl, HCT116−sh1, and HCT116−sh2 CRC cells (2 × 10 6 ) and housed for 30 days.

Techniques: Activity Assay, Expressing, Luciferase, Transfection, Recombinant, Plasmid Preparation

Journal: Translational Oncology

Article Title: ZNF37A downregulation promotes TNFRSF6B expression and leads to therapeutic resistance to concurrent chemoradiotherapy in rectal cancer patients

doi: 10.1016/j.tranon.2024.102203

Figure Lengend Snippet: Knocking down TNFRSF6B can restore the sensitivity of colorectal cancer to chemoradiotherapy. A. Colony formation assays of Knocking down TNFRSF6B in LoVo-shCtrl, LoVo-ZNF37A sh1 and LoVo-ZNF37A sh2, HCT116-shCtrl, HCT116-ZNF37A sh1, HCT116-ZNF37A sh2 cells. DMSO, control group treated with dimethyl sulfoxide. CT/RT, the treatment group treated with radiotherapy (2 Gy) and chemotherapy (5-Fu and Oxaliplatin). Data were shown as mean±SEM from three independent experiments. **, P < 0.01; ***, P < 0.001 and ns, not significant of Student's t -test. B. Detection of apoptosis-related proteins by western blot after chemoradiotherapy when knocking down TNFRSF6B in LoVo-shCtrl, LoVo-ZNF37A sh1 and LoVo-ZNF37A sh2, HCT116-shCtrl, HCT116-ZNF37A sh1, HCT116-ZNF37A sh2 cells. C. Scatter plots showed the effect of ZNF37A expression level on chemoradiotherapy sensitivity of CRC.

Article Snippet: Male BALB/c mice aged 4–6 weeks (Beijing IDMO Co.) were injected subcutaneously with HCT8−Vector, HCT8−ZNF37A, HCT116−shCtrl, HCT116−sh1, and HCT116−sh2 CRC cells (2 × 10 6 ) and housed for 30 days.

Techniques: Control, Western Blot, Expressing